Material Event (Form 8-K)

On September 20, 2021, Verrica Pharmaceuticals Inc. (the "Registrant") announced that it received a complete response letter from the U.S. Food and Drug Administration (the "FDA") identifying deficiencies at a facility of a contract manufacturing organization for its New Drug Application (the "NDA") for VP-102for the treatment of molluscum contagiosum. The identified deficiencies do not specifically relate to the manufacturing of VP-102,but instead raise general quality issues at the facility. The FDA did not identify any clinical, safety or product specific chemistry, manufacturing, and controls deficiencies related to the NDA.